logo
The Economy Is Slowing; Tariffs Make It Worse

The Economy Is Slowing; Tariffs Make It Worse

Forbes15-04-2025
The tariff file has caused a high level of uncertainty both for consumers and businesses. As a result, all it took was the lifting of that uncertainty, via the 90-day suspension of higher tariffs, for the equity market to surge on Wednesday, April 9th. That day, the DJIA rose +7.9%, Nasdaq +12.2%, the S&P 500 +9.5%, and even the small cap Russell 2000 +8.7%.1 For the week as a whole, all four indexes were positive, led by the tech heavy Nasdaq as shown in the third column of the table. Still, equity markets remain negative for the month and year to date.1
Equity Market
In addition, it appears that the markets haven't yet priced in a slowing economy (the latest Atlanta Fed Q1 GDP growth forecast is -2.4%).2 Another quarter of negative growth, as seems likely, will trigger the rule of thumb Recession call (i.e., two negative GDP growth quarters in a row) and would likely cause the National Bureau of Economic Research (NBER) to officially declare that the economy had entered a Recession.2
As further evidence of a slowing economy, the Challenger Gray and Christmas layoff data for March showed up at +275,240, the highest number for any March on record.3 Admittedly, much of this is due to DOGE's layoffs of federal employees. But we also note that Retail lost -57,000 jobs in March (vs. -12,000 in March 2024), and that hiring was down -37.5% from a year ago.3
The ISM Services Index fell in March to 50.8 from 53.5 in February (50 is the demarcation line between expansion and contraction).4 While still showing minimal expansion, the large March pullback does not bode well for the April reading.4
The National Federation of Independent Business' (NFIB) monthly business index fell to 97.4 in March from 100.7 in February.5 As the table shows, this index had a similar level at the beginning of the last six Recessions.
NFIB Index
Note that the recent 97.4 level fits right into the table.
The University of Michigan's (UM) Consumer Sentiment Index fell to 50.8 in April from 57.0 in March, quite the fall.10 Just for comparative purposes, this is the lowest level since June '22 (Covid) and the second lowest reading on record dating back to 1952! Worse, the Trump tariffs have convinced the public that they will usher in more inflation as UM's one-year inflation expectations index soared to 6.7% in April from March's already high 5.0% reading.6The 5-year inflation expectations reading rose to 4.4% (from 4.1% in March), the highest reading for this index since 1991!
University of Michigan Consumer Sentiment
With such public expectations, the Fed has little choice but to forgo any rate reductions at its upcoming May meeting set.
Despite the 90-day 'pause' in the tariff file for most countries, the risk of Recession is rising due to the 145% tariff on imports from China in addition to the high and rising level of uncertainty.7 Tariffs normally have a negative impact on profit margins. When uncertainty rises, business growth expectations fall, and they tend to delay any expansion plans. In addition, consumers become more cautionary and tend to spend less and save more.1 The following chart indicates that this process has already begun.
Consumer Expectations
With nominal income growth in the U.S. now showing weakness (i.e. the strong possibility of an oncoming Recession), that means either business profit margin compression or lower demand (or some combination of the two).9
During a Recession, the average equity market pullback is nearly -30%, normally over a 6 – 12-month period. And bond market yields fall by about 150 basis points (1.5 percentage points).11
Fed Chair Powell says the Fed is waiting for the softening survey data to translate into hard data before moving toward lower interest rates. This, even though his own Atlanta Fed has pegged Q1 GDP growth at -2.4%.2 (As noted, there already are many economic signs that the economy is cooling both on the business side and on the consumer side.) Because of the long lags between changes in monetary policy and their impact on the economy, it appears that the Fed should be lowering rates now when the soft data show a weakening economy, to adjust for those long lags.11
Despite the timing of policy changes, it is clear that the next move in monetary policy is to continue to lower rates. The Fed has told markets that the 'neutral' rate (known as R*) for the Federal Funds rate, is 3%. Right now, that Federal Funds rate is pegged between 4.25% and 4.50%. So, there's 125 to 150 basis points (i.e., 1.25 to 1.50 percentage points) of rate reduction just to get to neutral.11 But, as noted above, because of the recent rise in inflation expectations, it is unlikely that the Fed will lower rates at its May meeting, and is likely to wait for Powell's 'hard data' requirement (despite the negative growth rate of Q1 GDP).11
If a Recession actually develops, the Fed will have to take that Fed Funds rate below neutral (3%), how far depends on the severity of the economic slowdown. (We note that the major investment banks have significantly increased their odds of a Recession occurring in 2025.)
Falling interest rates mean rising bond prices with the prices of longer-term bonds benefitting most. A note of caution here. China's holdings of U.S. Treasury securities peaked at $1.3 trillion in 2014. Today, they stand at $700 billion.12 13 That still is a significant amount. The dumping of those securities could easily cause a spike in interest rates. In fact, we've recently seen a small spike in rates making us wonder if the selling has already begun.14
The 90-day tariff suspension lifted uncertainty (on Wall Street, 90-days is 'long-term') causing large-cap equities to bounce 5% - 7% for the week (small cap stocks were positive too, but to a lesser extent (+1.8%)). Nevertheless, it still appears that markets have not yet priced in a slowing economy and the rising probability of Recession.15
We continue to see evidence of an economic slowdown. Q1 GDP growth will be negative according to the Atlanta Fed (-2.4%). We see no catalyst to turn that around.
Layoff data were the highest for any March on record, which will soon translate into a higher unemployment rate.7
Other survey data, like the NFIB's monthly business index and the University of Michigan's Consumer Sentiment Index are also giving Recession signals.5 6
Tariffs, especially the large 145% rate on China, are bound to have negative impacts on business profit margins as well as a reduction in consumer demand as prices rise.7
The sudden rise in consumer inflation expectations, no doubt due to the tariffs, is bound to keep the Fed on the sidelines despite Q1's negative GDP reading. Chair Powell sees the softening survey data but insists that the Fed will wait for the hard data before it acts. In our view, because of the lag time between when the Fed acts and its impact on the economy, that's a mistake.11
(Joshua Barone and Eugene Hoover contributed to this blog.)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

U.S. Veterans Affairs will cut nearly 30,000 jobs, far fewer than planned
U.S. Veterans Affairs will cut nearly 30,000 jobs, far fewer than planned

Yahoo

time13 minutes ago

  • Yahoo

U.S. Veterans Affairs will cut nearly 30,000 jobs, far fewer than planned

By Christian Martinez (Reuters) -The U.S. Department of Veterans Affairs will make two-thirds fewer employee cuts this fiscal year than it first targeted, reducing staff by about 30,000 people rather than 80,000, the agency said on Monday. The agency employed about around 480,000 people at the start of the Trump administration and expects to end the fiscal year in September with nearly 450,000 staff. Under President Donald Trump's program to downsize the federal government, the agency had planned to reach just under 400,000 employees. That proposal drew widespread condemnation from military veteran groups and Democrats. The agency said in a statement it was on pace to reduce its staff "through the federal hiring freeze, deferred resignations, retirements and normal attrition." It did not say why it no longer needed to make further cuts. The scale of the original planned layoffs was far greater than proposed cuts at other government agencies and potentially posed a political risk for Trump, who portrays himself as a champion of the U.S. military and its members. Between January and June, the agency shed nearly 17,000 employees and expects "nearly 12,000 additional VA employees to exit" by September 30, the VA said. "A department-wide RIF is off the table, but that doesn't mean we're done improving VA," VA Secretary Doug Collins said in a release, referring to a reduction in force, which means permanent layoffs. Just under 9 million veterans were enrolled in the VA Health Care System in March, according to the VA website.

Veterans Affairs Dept. drops plan to lay off thousands in August
Veterans Affairs Dept. drops plan to lay off thousands in August

Yahoo

time13 minutes ago

  • Yahoo

Veterans Affairs Dept. drops plan to lay off thousands in August

The Department of Veterans Affairs has dropped plans revealed in a memo earlier this year to lay off tens of thousands of personnel in August, a news release from the department indicated Monday. The VA announced it's currently on pace to reduce its staff by about 30,000 employees by the end of this fiscal year, in September, thereby "eliminating the need for a large-scale reduction-in-force," or RIF. The department originally planned to reduce its staff to 2019 levels, or just under 400,000, according to a memo obtained by CBS News in March. The VA said in its release that it had "roughly 484,000 employees on Jan. 1, 2025" — meaning the initial plans would have required the VA to cut upwards of 80,000 jobs. In a statement included in the release, Secretary of Veterans Affairs Doug Collins said that as a result of a "holistic" department-wide review, the VA "is headed in the right direction — both in terms of staff levels and customer service. A department-wide RIF is off the table, but that doesn't mean we're done improving VA." The VA acknowledged in the release that the agency "had been considering a department-wide RIF to reduce staff levels by up to 15%," but said "employee reductions through the federal hiring freeze, deferred resignations, retirements and normal attrition have eliminated the need for that RIF." A spokesperson for the VA said in a statement Monday that it spent "nearly four months conducting a holistic review of the department to see what needs to be changed." The department claimed that in recent months, the VA has improved services for veterans, citing "huge drops in the number of Veterans waiting for disability benefits, sizeable increases in claims processing productivity, and extraordinary progress regarding our electronic health record modernization." The spokesperson said the original number of 80,000 staff cuts "got employees thinking outside of the box to come up with new and better ways of serving Veterans," and the "main goal all along has been creating the best possible experiences and outcomes" for veterans and their families. Under the Biden administration, the VA hired tens of thousands of workers, in part to help administer the PACT Act, which addresses toxic exposures veterans suffered while serving in the military. The Trump administration initially looked at cutting staff levels to pre-Biden administration levels. The Trump administration imposed a broader hiring freeze on many government jobs earlier this year, part of a push to cut the size of the federal workforce. The VA exempted some roles from that freeze, including many health care jobs at the agency's hospital network. The administration also offered a voluntary "deferred resignation" deal that allowed thousands of federal workers to leave their jobs in early February and get paid until September. Democratic Sen. Richard Blumenthal of Connecticut took note of the reversal of the planned mass layoffs at the VA and blamed the work environment at the department. "This announcement makes clear VA is bleeding employees across the board at an unsustainable rate because of the toxic work environment created by this Administration and DOGE's slash and trash policies," Blumenthal, the top Democrat on the Senate Veterans' Affairs Committee, said in a statement. "This is not 'natural' attrition, it is not strategic, and it will inevitably impact veterans' care and benefits — no matter what blanket assurances the VA Secretary hides behind." Blumenthal noted the VA workforce usually expands by about 10,000 "in a typical year," and its statement that it was losing 30,000 this year means the VA "still stands to lose tens of thousands more employees than ever before." He complained that the administration "repeatedly refused to share any additional information about this plan to cut 83,000 VA employees and what positions would be targeted." Death toll rises as desperate search for Texas flash flood survivors continues Sabrina Carpenter on the biggest misperceptions about her How Lady Liberty became a beacon for immigrants

UK MHRA Approves ImmunityBio's ANKTIVA ® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
UK MHRA Approves ImmunityBio's ANKTIVA ® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Business Wire

time21 minutes ago

  • Business Wire

UK MHRA Approves ImmunityBio's ANKTIVA ® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for ANKTIVA ® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of certain bladder cancer patients. This is the first marketing approval outside the U.S. for this novel lymphocyte-stimulating agent. 'With the MHRA's authorization of ANKTIVA plus BCG, we can now offer our immunotherapy outside the U.S. to help patients with a disease that, if not effectively treated, can lead to bladder removal,' said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. 'This immune-boosting, lymphocyte-stimulating agent, the first of its kind, is central to our Cancer BioShield platform, which is designed to restore immune function and support long-term disease control.' 'ImmunityBio is honored to have received this important authorization from the UK MHRA. In light of the United States Most-Favored-Nation Prescription Drug Pricing policy implemented on May 12, 2025, we are actively evaluating our go-to-market strategy for the UK,' said Richard Adcock, CEO and President of ImmunityBio. ANKTIVA is a first-in-class IL-15 agonist that activates and proliferates natural killer (NK) cells and CD4+ and CD8+ T cells. It is designed to restore immune competence by reversing lymphopenia—a condition in which cancer and conventional therapies, such as chemotherapy, radiation and checkpoint inhibitors, reduce the number and function of immune cells. Restoring immune function is essential for immunosurveillance, immunogenic cell death, and sustained tumor control. The BioShield platform's effectiveness can be monitored using a routine complete blood count (CBC). ANKTIVA was designated a Breakthrough Therapy by the FDA and received approval from both the FDA and MHRA based on its safety and efficacy outcomes of complete response (CR) and duration of response (DOR). In a single-arm, multicenter trial, 77 evaluable patients received ANKTIVA with BCG for up to 37 months. As of the November 2023 data cutoff, the duration of complete response for some patients exceeded 47 months and remains ongoing. These extended duration of complete responses beyond 24 months with ANKTIVA and BCG surpasses the benchmark for meaningful clinical results set by experts from the International Bladder Cancer Group. ImmunityBio has also submitted regulatory applications to the European Medicines Agency (EMA) to expand availability of ANKTIVA across the 27 European Union (EU) member states, as well as Iceland, Norway and Liechtenstein. About NMIBC CIS Bladder cancer is the 10th most commonly-diagnosed cancer globally, 2 and in the UK, the Action Bladder Cancer UK estimates approximately 23,000 patients are diagnosed annually. 1 At the time of diagnosis, about 80% of cases are non-muscle invasive bladder cancer (NMIBC), wherein the cancer is found only on the inner layer of the bladder wall. 3 The standard therapy for NMIBC is intravesical instillation (delivery to the bladder via a catheter) of Bacillus Calmette-Guerin (BCG). 4,5 BCG is a benign bacteria that induces an immune response in the bladder in proximity to the cancer cells, leading to clearance of the cancer in many patients. In ~30-40% of patients, however, BCG will fail, and in ~50% that initially respond, cancer will recur. 6 About ANKTIVA The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and drives the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. The proliferation of the trifecta of these immune killing cells and the activation of trained immune memory results in immunogenic cell death, inducing a state of equilibrium with durable complete responses. ANKTIVA has improved pharmacokinetic properties, longer persistence in lymphoid tissues, and enhanced anti-tumor activity compared to native, non-complexed IL-15 in-vivo. ANKTIVA was approved by the FDA in 2024 for BCG-unresponsive non-muscle invasive bladder cancer CIS with or without papillary tumors. For more information, visit INDICATION AND IMPORTANT SAFETY INFORMATION FROM THE FDA LABEL INDICATION AND USAGE: ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patient with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For lntravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours. USE IN SPECIFIC POPULATIONS: Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. ADVERSE REACTIONS: The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia. For more information about ANKTIVA, please see the Full Prescribing Information at You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-332-1088. You may also contact lmmunityBio at 1-877-ANKTIVA (1-877-265-8482) About ImmunityBio ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. References: Action Bladder UK. Non-muscle invasive bladder cancer. May 2021. Available at: World Cancer Research Fund. Bladder Cancer Statistics. 2022. Available at: Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Canadian Urological Association Journal, 4(1), 56–64. Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024;10.1097/JU.0000000000003846. Grabe-Heyne, et al. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023 Jun 2;13:1170124. doi: 10.3389/fonc.2023.1170124. Kodera A, Mohammed M, Lim P, Abdalla O, Elhadi M. The Management of Bacillus Calmette-Guérin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article. Cureus. 2023 Jun 26;15(6):e40962. doi: 10.7759/cureus.40962. PMID: 37503461; PMCID: PMC10369196. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding clinical trial data and potential results and implications to be drawn therefrom, the belief that the MHRA authorization leads to increased revenue, the expectation that the EAP as previously reported will enable access to ANKTIVA for patients across all solid tumor types who have exhausted first-line therapy including chemo, radiation or immunotherapy, the RMAT designation as previously reported and potential results therefrom and regulatory submissions in connection therewith, the belief that ALC levels and NLR levels obtained from a CBC are predictors of clinical benefit and outcomes relating to overall survival, the belief that improving ALC levels and NLR levels correlates with enhanced overall survival and clinical benefit, the belief that reversal of lymphopenia correlates with improved survival, clinical trial and expanded access program enrollment, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's Cancer BioShield platform, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents for the prevention or reversal of lymphopenia, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that has the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, and the impact of the MHRA on the Company's ex-United States go to market strategy, including in light of the recently implemented United States Most Favored Nation pricing policy on the Company's go-to-market strategy in the United Kingdom, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as 'anticipates,' 'believes,' 'continues,' 'goal,' 'could,' 'estimates,' 'scheduled,' 'expects,' 'intends,' 'may,' 'plans,' 'potential,' 'predicts,' 'indicate,' 'projects,' 'is,' 'seeks,' 'should,' 'will,' 'strategy,' and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding the FDA regulatory submission, filing and review process and the timing thereof, (ii) risks and uncertainties regarding regulatory submissions in foreign jurisdictions, filing and review process and the timing thereof, (iii) whether the RMAT designation will lead to an accelerated review or approval, of which there can be no assurance, (iv) risks and uncertainties regarding commercial launch execution, success and timing, (v) risks and uncertainties regarding participation and enrollment and potential results from the expanded access clinical investigation program described herein, (vi) whether clinical trials will result in registrational pathways and the risks, (vii) whether clinical trial data will be accepted by regulatory agencies, (viii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (iv) potential delays in product availability and regulatory approvals, (x) ImmunityBio's ability to retain and hire key personnel, (xi) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (xii) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xiii) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xiv) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xv) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading 'Risk Factors' in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on May 12, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store